ZEVRA THERAPEUTICS INC (ZVRA) Stock Price, Forecast & Analysis
NASDAQ:ZVRA • US4884452065
ZVRA Key Statistics, Chart & Performance
The current stock price of ZVRA is 8.93 USD. In the past month the price increased by 0.79%. In the past year, price increased by 11.49%.
ZVRA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ZVRA. When comparing the yearly performance of all stocks, ZVRA turns out to be only a medium performer in the overall market: it outperformed 62.56% of all stocks.
ZVRA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ZVRA. Both the profitability and financial health of ZVRA have multiple concerns.
ZVRA Financial Highlights
Over the last trailing twelve months ZVRA reported a non-GAAP Earnings per Share(EPS) of 0.45. The EPS increased by 122.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 41.86% | ||
| ROA | 13.08% | ||
| ROE | 26.53% | ||
| Debt/Equity | 0.46 |
ZVRA Forecast & Estimates
14 analysts have analysed ZVRA and the average price target is 23.31 USD. This implies a price increase of 161.08% is expected in the next year compared to the current price of 8.93.
For the next year, analysts expect an EPS growth of 155.85% and a revenue growth 389.32% for ZVRA
ZVRA Ownership
ZVRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.88 | 296.105B | ||
| PFE | PFIZER INC | 9.21 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 124.384B | ||
| ZTS | ZOETIS INC | 19.09 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.184B | ||
| VTRS | VIATRIS INC | 5.9 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZVRA
Company Profile
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 59 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Company Info
ZEVRA THERAPEUTICS INC
1180 Celebration Boulevard, Suite 103
Celebration FLORIDA US
Employees: 59
Phone: 18009279800
ZEVRA THERAPEUTICS INC / ZVRA FAQ
What does ZVRA do?
Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The company is headquartered in Celebration, Florida and currently employs 59 full-time employees. The company went IPO on 2015-04-16. The company has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
What is the current price of ZVRA stock?
The current stock price of ZVRA is 8.93 USD. The price decreased by -1.76% in the last trading session.
Does ZVRA stock pay dividends?
ZVRA does not pay a dividend.
How is the ChartMill rating for ZEVRA THERAPEUTICS INC?
ZVRA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the GICS sector and industry of ZVRA stock?
ZEVRA THERAPEUTICS INC (ZVRA) operates in the Health Care sector and the Pharmaceuticals industry.
How is the valuation of ZEVRA THERAPEUTICS INC (ZVRA) based on its PE ratio?
The PE ratio for ZEVRA THERAPEUTICS INC (ZVRA) is 19.84. This is based on the reported non-GAAP earnings per share of 0.45 and the current share price of 8.93 USD.
Can you provide the upcoming earnings date for ZEVRA THERAPEUTICS INC?
ZEVRA THERAPEUTICS INC (ZVRA) will report earnings on 2026-03-09, after the market close.